+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 10 Actively Recruiting clinical trials

P

Actively Recruiting

This research aims to evaluate the long-term safety of luspatercept in participants who have previously taken part in other luspatercept clinical trials for conditions such as Myelodysplastic Syndromes MDS, Beta-thalassemia, and Myeloproliferative Neoplasm-associated Myelofibrosis. It is a Phase 3b, open-label, single-arm rollover study designed to continue monitoring participants who tolerated previous luspatercept treatment and may benefit from ongoing therapy, as well as those in post-treatment follow-up phases. Participants transitioning from prior luspatercept studies will enter a Transition Phase defined by an enrollment visit. Those continuing treatment will receive luspatercept injections subcutaneously at the same dose and schedule as their parent trial, administered by study staff at clinical sites. The study includes a Treatment Phase for ongoing luspatercept administration and a Follow-up Phase comprising a 42-day safety follow-up after the last dose and a long-term post-treatment follow-up phase lasting at least 5 years to monitor overall survival and progression to malignancies. Throughout the study, participants will be regularly assessed for adverse events, progression to high-risk MDS or AML, and development of other malignancies or treatment-related masses. Safety parameters are evaluated during the 42-day follow-up, while long-term survival and disease progression are monitored every six months for at least five years. The study will conclude when all participants have completed five years of combined treatment and follow-up.

Age: 18Years +All GendersPhase 3
143 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of inavolisib combined with Phesgo compared to placebo with Phesgo as maintenance treatment after initial therapy in people with untreated HER2-positive advanced breast cancer that has a PIK3CA mutation. This phase III trial focuses on how well the treatments control the disease and their side effects. Participants first receive induction therapy with Phesgo plus taxane-based chemotherapy. Afterward, they receive maintenance therapy with either inavolisib plus Phesgo or placebo plus Phesgo in 21-day cycles. Phesgo is given by subcutaneous injection every 3 weeks, while inavolisib or placebo tablets are taken daily on days 1 to 21 of each cycle. Optional endocrine therapy may also be provided according to standard care. During the study, participants undergo regular assessments including tumor evaluations, heart function tests, laboratory tests, and quality of life questionnaires. Researchers monitor progression-free survival up to about 40 months and overall survival and other outcomes up to approximately 111 months. Participants are followed closely for adverse events and drug levels. The total study duration may extend up to nearly 10 years, with visits scheduled throughout treatment and follow-up periods.

Age: 18Years +All GendersPhase 3
192 locations
I

Actively Recruiting

Researchers are investigating autoinflammatory diseases AID, which involve recurring inflammatory episodes without infection, cancer, or adaptive immune system problems. This study focuses on both monogenic hereditary periodic syndromes and polygenic or multifactorial AID, including rare conditions like Behets disease, Still disease, Schnitzlers disease, PFAPA syndrome, chronic recurrent multifocal osteomyelitis, non-infectious uveitis and scleritis, among others. The goal is to gather detailed data to improve understanding and management of these rare diseases through an international collaboration. The study uses the AIDA registry, a secure online platform for collecting demographic, genetic, clinical, laboratory, radiologic, and therapeutic information. Data are gathered retrospectively and prospectively during routine clinical visits scheduled every 3-6 months. Eleven registries focus on different AID conditions, enabling comprehensive data collection to identify clinical patterns, treatment impacts, and long-term outcomes over a period of at least 10 years. Participants provide information during their usual care visits, allowing researchers to track changes in disease activity, organ involvement, inflammatory markers, visual function, pain levels, fatigue, fertility, and socioeconomic factors. The study monitors these outcomes over multiple timepoints up to 120 months. Data privacy is ensured by pseudonymizing patient information. This registry supports multiple clinical studies and aims to enhance knowledge, awareness, and future research on autoinflammatory diseases worldwide.

All AgesAll Genders
112 locations
S

Actively Recruiting

Researchers are observing the safety and clinical performance of the biodegradable polymer-coated Supraflex Cruz Sirolimus-eluting Stent in patients with multivessel coronary artery disease who need coronary revascularization using drug-eluting stents. This study includes a broad group of patients reflecting everyday clinical practice, including those with chronic coronary artery disease and acute coronary syndromes such as STEMI and NSTEMI. It aims to gather real-world data on this stents use in multiple vessel treatments. The study involves the use of the Supraflex Cruz Sirolimus-eluting Coronary Stent System, which is a biodegradable polymer-coated cobalt-chromium stent releasing sirolimus. All treated vessels will exclusively receive this stent during the procedure. Patients are followed according to routine clinical practice, with scheduled follow-ups either by phone or in person at 30 days, 6 months, and 12 months after the initial procedure. The study also plans subgroup analyses based on clinical presentation and lesion characteristics. Participants will undergo standard clinical evaluations and follow-up visits over one year to monitor outcomes such as Target Lesion Failure, mortality, myocardial infarction, revascularization, stent thrombosis, and target vessel failure. Follow-ups are designed to align with regular care schedules and include telephonic or clinical assessments. The total participation time for each patient is approximately 12 months, allowing researchers to collect comprehensive data on stent performance and patient safety in a real-world setting.

Age: 18Years - 99YearsAll Genders
2 locations
E

Actively Recruiting

Researchers are evaluating the effects of daily supplementation with Nitraria retusa dried crushed leaves infusion over 90 days on metabolic side effects caused by clozapine treatment in patients with treatment-resistant schizophrenia. This pilot, pre-experimental study focuses on patients who have developed obesity or central obesity after starting clozapine and aims to assess both the efficacy and tolerability of this supplement as an addition to their usual medications. Participants will take a daily infusion of Nitraria retusa extract at about 9 PM for 90 consecutive days while maintaining their usual diet and lifestyle. The infusion is prepared from 2,000 mg of finely crushed Nitraria retusa leaves steeped in 100 mL of boiled water for 15 minutes. Clinical and biological evaluations will be conducted at baseline, day 10, day 30, day 45, day 60, and day 90 to monitor changes and safety. During the study, participants will undergo assessments including body weight, waist circumference, other anthropometric measurements, body composition analysis, and metabolic panels such as blood glucose and cholesterol levels. Blood samples are collected after a 12-hour fast, and safety is monitored through complete blood counts, kidney and liver function tests. Participants provide informed consent and can withdraw at any time without affecting their usual care. The study duration for each participant is 90 days with multiple evaluations throughout this period.

Age: 18Years - 65YearsAll GendersPhase Not Applicable
1 location
I

Actively Recruiting

Healthy Volunteer

Researchers are investigating the outcomes for mothers diagnosed with cancer during pregnancy, focusing on overall survival and the long-term development of children exposed to cancer or cancer treatments before birth. The study aims to understand how prenatal exposure to therapies like chemotherapy, radiation, or targeted treatments may affect childrens neurological and heart health as they grow. The study includes several parts initially, it registers and tracks maternal and neonatal health during pregnancy and delivery, including collecting blood samples and tissue biopsies. Emotional needs of parents facing a cancer diagnosis are assessed through questionnaires. The second part follows children exposed in utero to cancer treatments with regular check-ups at various ages up to adulthood, including neurological and cardiological exams, and optional MRI sessions. Participants will undergo scheduled assessments including blood sample collection, placental biopsies, and questionnaires for parents. Children will have neurological and heart evaluations at set ages from 6 months through 18 years, with further cardiologic monitoring every five years into adulthood. The research team monitors overall survival in mothers and developmental outcomes in children, ensuring comprehensive long-term follow-up extending potentially into the fourth decade of life for offspring.

Age: 18Years +FEMALE
33 locations
A

Actively Recruiting

Researchers are studying adult patients who come to the emergency department with sudden shortness of breath dyspnea to evaluate how well the CardioStory device can distinguish heart failure from other causes. This observational study collects data from routine clinical assessments, including medical history, physical exams, laboratory tests, and echocardiography results. The goal is to assess the diagnostic performance of this non-invasive technology in a real-world emergency setting. The CardioStory device is a non-invasive medical tool designed to quickly measure cardiac filling pressure using fiber-optic sensors and advanced algorithms, without the need for catheterization or injectable substances. Patients will be assessed using this device alongside standard clinical evaluations to compare results. The measurement process is rapid, taking about 2 minutes, and aims to be simple and reproducible. Participants involvement includes undergoing routine clinical assessments and the CardioStory device measurement during their emergency visit. Researchers will collect data on diagnostic accuracy, sensitivity, specificity, time required for measurements, and any adverse events related to the device on the first day. The total study duration extends until December 2026, with data collected primarily during the initial emergency department visit.

Age: 18Years +All Genders
2 locations
V

Actively Recruiting

This research aims to validate the Glasgow-Blatchford Score GBS in adults presenting with non-traumatic upper gastrointestinal bleeding in Tunisia. The study addresses the challenge of routinely hospitalizing all patients for observation by evaluating whether GBS can accurately predict risks like rebleeding, the need for hemostatic treatment, complications, and mortality within 30 days. It is a multicenter, descriptive, and analytical observational study conducted in emergency departments. Adult patients aged 18 years and older with non-traumatic upper gastrointestinal bleeding will be included. Clinical and epidemiological information will be collected using a standard form that incorporates GBS criteria. Follow-up will occur 30 days after initial presentation to track adverse outcomes including rebleeding, need for intervention, complications, and death. The performance of the GBS will be assessed statistically for sensitivity, specificity, and predictive values. Participants will have their clinical data recorded at emergency department visits. A telephone follow-up at 30 days will gather information about any complications or mortality. Researchers will analyze the data to determine how well the GBS predicts outcomes in this population. The total duration of involvement per participant will be approximately 30 days, with confidentiality and informed consent ensured throughout the study.

Age: 18Years +All Genders
1 location
E

Actively Recruiting

Axial myopia is a form of nearsightedness caused by the eye being too long from front to back, leading to blurry distant vision. It typically begins in childhood and worsens as the eyes grow longer, potentially causing serious eye issues later in life. Researchers are studying T10430 eye drops to see if they can slow or stop this progression in children aged 6 to 11 years, aiming to prevent more severe complications. This Phase 2 trial also evaluates the safety of T10430 based on encouraging animal study results. Participants will be randomly assigned to receive one of three different strengths of T10430 eye drops or a placebo. Each participant will instill one drop in each eye once daily at around 8 PM for up to 56 weeks, followed by a 4-week follow-up period. The study will include about 200 children with axial myopia, and the treatments will be given under double-blind conditions so neither participants nor researchers know which dose is administered. Throughout the study, children and their guardians will attend visits for physical and eye examinations to monitor safety and treatment effects. Researchers will measure treatment-emergent adverse events during the entire study period of up to 60 weeks. They will also assess changes in axial eye length and spherical equivalent refraction at 6 and 12 months. This careful monitoring aims to understand how T10430 impacts eye growth and vision while ensuring participant safety.

Age: 6Years - 11YearsAll GendersPhase 2
10 locations
V

Actively Recruiting

Heart failure is a common and serious condition that leads to many hospital visits and deaths worldwide. Access to specialized heart failure clinics is limited, although such care can improve patient outcomes. This international, multicenter randomized controlled trial called VICTORY-HF is studying whether adding a virtual heart failure clinic to routine care can improve medication use and health outcomes for patients recently discharged after hospitalization or urgent care for heart failure. Participants will be randomly assigned to receive either 90 days of virtual heart failure clinic care plus routine care or routine care alone. The virtual clinic offers structured remote follow-up, monitoring of physiological measures, and optimization of guideline-directed medical therapies. The trial will evaluate the effects of this intervention on medication use, patient-reported health status, mortality, hospital readmissions, and emergency visits. Participants will be followed for 90 days during the virtual clinic intervention, with co-primary outcomes measured at 90 and 180 days. Assessments include monitoring of clinical events, medication optimization, and healthcare utilization. The follow-up period includes clinic visits and data collection to evaluate the impact of virtual care on recovery and health status after heart failure hospitalization.

Age: 18Years +All GendersPhase Not Applicable
9 locations